Xencor News

Buy Rating Affirmed for Xencor: Strong Q1 Financials, FDA Approval, and Promising Pipeline Signal Growth Potential

TipRanksMay 14 16:38

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Neurogene (NGNE)

TipRanksMay 13 08:20

Xencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings Estimates

Yahoo FinanceMay 11 01:45

Xencor Is Maintained at Outperform by Wedbush

Xencor Is Maintained at Outperform by Wedbush

Dow JonesMay 10 21:49

Wedbush: The Xencor (XNCR.US) rating was maintained, and the target price was adjusted from superior to superior to the market rating, and the target price was adjusted from $34.00 to $36.00.

Wedbush: The Xencor (XNCR.US) rating was maintained, and the target price was adjusted from superior to superior to the market rating, and the target price was adjusted from $34.00 to $36.00.

Zhitong FinanceMay 10 21:40

Xencor Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 54.57% Wedbush $34 → $36 Maintains Outperform 04/16/2024 63.16% BTIG $56 → $38 Maintains Buy 02

BenzingaMay 10 21:38

Xencor (XNCR) Receives a New Rating From Wedbush

TipRanksMay 10 20:46

Buy Rating Affirmed for Xencor on Strategic Focus and Strong Financial Position

TipRanksMay 10 20:26

Buy Rating Affirmed for Xencor on Strong Pipeline and Financials: Anticipated IND Filing and T-cell Engager Developments

TipRanksMay 10 20:17

Piper Sandler Keeps Their Hold Rating on Xencor (XNCR)

TipRanksMay 10 20:04

Wedbush Adjusts Xencor's Price Target to $36 From $34, Keeps Outperform Rating

Xencor (XNCR) has an average rating of outperform and price targets ranging from $22 to $58, according to analysts polled by Capital IQ.

MT NewswiresMay 10 18:20

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sangamo Biosciences (SGMO), Xencor (XNCR) and Evolent Health (EVH)

TipRanksMay 10 17:50

Xencor (XNCR.US): The 2024 Q1 financial report achieved revenue of US$1.805 million, with a previous value of US$18.962 million and an expected value of US$24.99 million; earnings per share was -1.11 USD, previous value of -1.02 USD, and expected value of

Xencor (XNCR.US): The 2024 Q1 financial report achieved revenue of US$1.805 million, with a previous value of US$18.962 million and an expected value of US$24.99 million; earnings per share was -1.11 USD, previous value of -1.02 USD, and expected value of -0.79 USD.

Zhitong FinanceMay 10 07:40

Xencor Q1 2024 GAAP EPS $(1.11) Misses $(0.78) Estimate, Sales $12.805M Miss $24.992M Estimate

Xencor (NASDAQ:XNCR) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.78) by 42.31 percent. The company reported quarterly sales of $12.805 million wh

BenzingaMay 10 05:26

Earnings Flash (XNCR) XENCOR Reports Q1 Revenue $12.8M

04:09 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (XNCR) XENCOR Reports Q1 Revenue $12.8M

MT NewswiresMay 10 04:09

Xencor 1Q Loss/Shr $1.11 >XNCR

Xencor 1Q Loss/Shr $1.11 >XNCR

Dow JonesMay 10 04:09

Xencor Reports First Quarter 2024 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today

BusinesswireMay 10 04:09

Xencor | 10-Q: Quarterly report

Futu NewsMay 10 04:04 · Announcements

Amidst Increasing Losses, Investors Bid up Xencor (NASDAQ:XNCR) 14% This Past Week

While not a mind-blowing move, it is good to see that the Xencor, Inc. (NASDAQ:XNCR) share price has gained 26% in the last three months. But that cannot eclipse the less-than-impressive returns ov

Simply Wall StMay 6 18:21

Insider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells Shares

Yahoo FinanceMay 4 07:01